Metsera (MTSR) Stock Price, News & Analysis

Company Overview

Metsera, headquartered in Centennial, Colorado, is a medical technology company specializing in the design and manufacture of fluid filtration and purification systems. Founded in 2010, the firm originally focused on developing inline ultrafiltration solutions for dialysis applications and later rebranded as Metsera in 2020 following a strategic merger. Through this evolution, the company has established itself as a provider of high-purity filtration components that enhance the safety and efficacy of critical fluid pathways in healthcare and life sciences.

At the core of Metsera’s product portfolio is its AISTR® (Automatic Inline Sterile Delivery) ultrafilter, engineered to remove bacteria, endotoxins and submicron particulates from fluid streams. In addition to its flagship ultrafilter cartridge, the company offers custom-engineered filtration modules, disposable fluid pathway assemblies and validation services to support rigorous regulatory requirements. These solutions are utilized in renal care, biotechnology manufacturing, laboratory instrumentation and other applications where fluid purity is paramount.

Metsera serves a global customer base that includes original equipment manufacturers (OEMs), healthcare systems and contract manufacturing organizations across North America, Europe and the Asia-Pacific region. The company holds ISO 13485 certification and CE marking, facilitating access to regulated markets worldwide. By forging strategic distribution partnerships and maintaining dedicated technical support teams, Metsera has expanded its presence to more than 25 countries and continues to drive adoption of its filtration technologies among leading medical device and life sciences firms.

Led by a management team with extensive experience in medical device development, regulatory affairs and global commercialization, Metsera places a strong emphasis on research and development to enhance product performance and production scalability. The executive leadership draws on backgrounds at major healthcare and life sciences companies, combining deep technical expertise with commercial acumen. Looking ahead, Metsera plans to advance next-generation filtration systems, pursue collaborative OEM engagements and explore targeted acquisitions to accelerate its growth trajectory in high-purity fluid management.

Key Stats

• Today's Range: $28.49 to $29.43
• 50-Day Range: $22.74 to $35.10
• 52-Week Range: $12.30 to $37.99
• Volume: 258,135 shs
• Average Volume: 907,035 shs
• Market Capitalization: $3.09 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $55.00
• Consensus Rating: Buy

MTSR Stock Analysis - Frequently Asked Questions

How have MTSR shares performed this year?

Metsera's stock was trading at $29.50 at the beginning of 2025. Since then, MTSR shares have decreased by 1.1% and is now trading at $29.17.

How were Metsera's earnings last quarter?

Metsera Inc. (NASDAQ:MTSR) announced its quarterly earnings data on Monday, May, 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

When did Metsera IPO?

Metsera (MTSR) raised $275 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $18.00 per share.

When does the company's lock-up period expire?

Metsera's lock-up period expires on Wednesday, July 30th. Metsera had issued 15,277,778 shares in its public offering on January 31st. The total size of the offering was $275,000,004 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

How do I buy shares of Metsera?

Shares of MTSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:MTSR
• Previous Symbol: NASDAQ:MTSR
• CIK: 2040807
• Web: N/A
• Phone: (212) 784-6595
• Fax: N/A
• Employees: 81
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $55.00
• High Stock Price Target: $65.00
• Low Stock Price Target: $38.00
• Potential Upside/Downside: +93.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.55
• Quick Ratio: 6.55

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.46) per share
• Price / Book: -11.54

Miscellaneous

• Outstanding Shares: 105,060,000
• Free Float: N/A
• Market Cap: $2.98 billion
• Optionable: N/A
• Beta: N/A